Current Evidence and Directions for Intermittent Fasting During Cancer Chemotherapy
Advances in Nutrition · 2022
DOI: 10.1093/advances/nmab132 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advances in Nutrition, 2022. Verfasst von Kelsey Gabel und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Kinesiology and Nutrition, University of Illinois at Chicago, Chicago, IL, USA. Electronic address: kdipma2@uic.edu. Hauptthemen laut MEDLINE: Obesity, Neoplasms. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIDDK NIH HHS, NIH.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Almost 40% of the adult population in the USA will be diagnosed with cancer in their lifetime. Diet is a modifiable factor which is known to affect cancer risk and recurrence. Yet, little is known about how diet influences cancer treatment outcomes. Intermittent fasting, characterized by periods of abstaining from foods and beverages alternated with periods of ad libitum intake, when adopted in the context of chemotherapy, has shown promise in preclinical models resulting in decreased vomiting, diarrhea, visible discomfort, and improved insulin sensitivity and efficacy of chemotherapeutic treatment. Although intermittent fasting during receipt of chemotherapy has been well-established in preclinical models, limited numbers of human studies are now being reported. This review aims to survey the current data examining the effect of intermittent fasting on chemotherapy efficacy, patient treatment outcomes, patient centered outcomes, and circulating biomarkers associated with cancer. Available data show that periodic fasting, a form of intermittent fasting, may hold potential to improve the effectiveness of chemotherapy, decrease treatment-related side effects and cancer-promoting factors such as insulin, while ameliorating treatment-related decreases in quality of life and daily functioning. Larger controlled periodic fasting trials, including exploration of alternate forms of intermittent fasting, are needed to better elucidate the effect of intermittent fasting on treatment and patient outcomes during chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Kinesiology and Nutrition, University of Illinois at Chicago, Chicago, IL, USA. Electronic address: kdipma2@uic.edu.
- Department of Kinesiology and Nutrition, University of Illinois at Chicago, Chicago, IL, USA.
- Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA; University of Illinois Cancer Center, Chicago, IL, USA.
- Department of Kinesiology and Nutrition, University of Illinois at Chicago, Chicago, IL, USA; University of Illinois Cancer Center, Chicago, IL, USA.
Förderung
- NCI NIH HHS
- NIDDK NIH HHS
- NIH
Zitieren
APA
Gabel, K., Cares, K., Varady, K., Gadi, V., & Tussing-Humphreys, L. (2022). Current Evidence and Directions for Intermittent Fasting During Cancer Chemotherapy. Advances in Nutrition. https://doi.org/10.1093/advances/nmab132
Vancouver
Gabel K, Cares K, Varady K, Gadi V, Tussing-Humphreys L. Current Evidence and Directions for Intermittent Fasting During Cancer Chemotherapy. Advances in Nutrition. 2022. doi:10.1093/advances/nmab132
BibTeX
@article{Gabel2022,
author = {Gabel, Kelsey and Cares, Kate and Varady, Krista and Gadi, Vijayakrishna and Tussing-Humphreys, Lisa},
title = {Current Evidence and Directions for Intermittent Fasting During Cancer Chemotherapy},
journal = {Advances in Nutrition},
year = {2022},
doi = {10.1093/advances/nmab132}
}
EUVIMED